BioMarin Pharmaceutical Inc. (BMRN): Price and Financial Metrics

BioMarin Pharmaceutical Inc. (BMRN)

Today's Latest Price: $77.33 USD

1.92 (-2.42%)

Updated Oct 19 9:50pm

Add BMRN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

BMRN Stock Summary

  • BMRN's current price/earnings ratio is 117.55, which is higher than 92.92% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for BMRN is currently 102.65, higher than 96.41% of US stocks with positive operating cash flow.
  • Over the past twelve months, BMRN has reported earnings growth of -180.67%, putting it ahead of only 10.44% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Biomarin Pharmaceutical Inc, a group of peers worth examining would be CREE, ACAD, CERS, PSNL, and JNPR.
  • BMRN's SEC filings can be seen here. And to visit Biomarin Pharmaceutical Inc's official web site, go to

BMRN Stock Price Chart Interactive Chart >

Price chart for BMRN

BMRN Price/Volume Stats

Current price $77.33 52-week high $131.95
Prev. close $79.25 52-week low $67.10
Day low $76.95 Volume 1,211,400
Day high $80.12 Avg. volume 1,836,842
50-day MA $82.38 Dividend yield N/A
200-day MA $94.62 Market Cap 14.02B

BioMarin Pharmaceutical Inc. (BMRN) Company Bio

BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company was founded in 1996 and is based in San Rafael, California.

BMRN Latest News Stream

Event/Time News Detail
Loading, please wait...

BMRN Latest Social Stream

Loading social stream, please wait...

View Full BMRN Social Stream

Latest BMRN News From Around the Web

Below are the latest news stories about Biomarin Pharmaceutical Inc that investors may wish to consider to help them evaluate BMRN as an investment opportunity.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - BMRN

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the…

PR Newswire | October 2, 2020

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of BioMarin Pharmaceuticals Inc. (BMRN) Investors

LOS ANGELES--(BUSINESS WIRE)---- $BMRN #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired BioMarin Pharmaceuticals Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020 (the “Class Period”). BioMarin investors have until November 24, 2020 to file a lead plaintiff motion. If you are a shareholder who suffered a loss, click here to participate. On A

Business Wire | October 2, 2020

BMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: November 24, 2020

NEW YORK, Sept. 30, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) and certain of its officers, on behalf of…

PR Newswire | September 30, 2020

BIOMARIN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company’s securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”). This action is pending in the United States Distric

Business Wire | September 30, 2020

Akero Continues Efruxifermin Trial, And Other News: The Good, Bad And Ugly Of Biopharma

Akero Therapeutics to continue with Mid stage Efruxifermin trial Akero Therapeutics Inc. (AKRO) reported that the company has received a written guidance from the FDA, allowing the company to pursue a novel combined Phase 2b/3 study design for pivotal efruxifermin ((EFX)) trials in NASH patients. The proposed trial design entails...

Avisol Capital Partners on Seeking Alpha | September 29, 2020

Read More 'BMRN' Stories Here

BMRN Price Returns

1-mo -2.58%
3-mo -40.47%
6-mo -16.37%
1-year 11.83%
3-year -11.87%
5-year -25.60%
YTD -8.54%
2019 -0.70%
2018 -4.51%
2017 7.64%
2016 -20.92%
2015 15.88%

Continue Researching BMRN

Here are a few links from around the web to help you further your research on Biomarin Pharmaceutical Inc's stock as an investment opportunity:

Biomarin Pharmaceutical Inc (BMRN) Stock Price | Nasdaq
Biomarin Pharmaceutical Inc (BMRN) Stock Quote, History and News - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7996 seconds.